Renovaro Inc

WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
CUSIP
29350E104
SEDOL
BD3NJQ5
CIK
0001527728
www.enochianbio.com
LEI: 5493003O12Q6PNJ56V39
©
New: Infographics X-Lab
Enochian Biosciences is a Member of Themefolio
          Hindenburg (TTF)          
FIGI: BBG0060CNMG8
ENOB
Renovaro Inc
GICS: - · Sektor: Healthcare · Sub-Sektor: Biotechnology
AI
PROFILER
NAME
Renovaro Inc
ISIN
US29350E1047
TICKER
ENOB
MIC
XNAS
REUTERS
RENB.OQ
BLOOMBERG
ENOB US
F&G: 64
6.449,26 S&P · 15,78 Vola-Index · 117.233,21 BTC · 1,17048 EURUSD
BUILD THEMEFOLIO IDEEN TEILEN DISKUTIEREN
HEBEL INVESTIEREN
Financial Intelligence
360° iHub Crowd ATH Tracker Index Tracker ETF TF Spicy X-Billboard
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von ACCESS Newswire bereitgestellt.
Fr., 08.08.2025       Enochian Biosciences
US29350E1047

LOS ANGELES, CALIFORNIA / ACCESS Newswire / August 8, 2025 / Renovaro Inc. (NASDAQ:RENB) was referenced in a recent RealClearDefense article titled "AI Can Be Used to Develop Biological and Chemical Weapons", which examines the complex challenges posed by artificial intelligence in the context of global security and biodefense.The full ar...
Read More
Enochian Biosciences
Technical Analysis Termsheet Terminal
Permalink
Mo., 28.07.2025       Enochian Biosciences
US29350E1047

Strategic IP expansion protects federated learning technology driving pharma partnerships, biosecurity initiatives, and precision medicine growth LOS ANGELES, CALIFORNIA / ACCESS Newswire / July 28, 2025 / Renovaro (NASDAQ:RENB), a precision-medicine technology company, today announced multiple U.S. patent allowances that significantly strengthen i...
Read More
Enochian Biosciences
Technical Analysis Termsheet Terminal
Permalink
Do., 17.07.2025       Enochian Biosciences
US29350E1047

Landmark preclinical data validate Renovaro's platform representing a step forward in the fight against pancreatic and solid tumors LOS ANGELES, CALIFORNIA / ACCESS Newswire / July 17, 2025 / Renovaro Biosciences (NASDAQ:RENB), an oncology and neurology focused TechBio company, today announced the publication of a peer-reviewed study in Vaccines, a...
Read More
Enochian Biosciences
Technical Analysis Termsheet Terminal
Permalink
Mi., 09.07.2025       Enochian Biosciences
US29350E1047

LOS ANGELES, CA / ACCESS Newswire / July 9, 2025 / Renovaro Inc. (NASDAQ:RENB), an AI-driven precision medicine company, today announced that senior debt holders have agreed to convert an aggregate of approximately $9.7 million of outstanding senior debt into convertible debt which they have elected to convert into equity.Under the terms of the ag...
Read More
Enochian Biosciences
Technical Analysis Termsheet Terminal
Permalink
Mo., 30.06.2025       Enochian Biosciences
US29350E1047

LOS ANGELES, CALIFORNIA / ACCESS Newswire / June 30, 2025 / Renovaro Inc.'s (NASDAQ:RENB) wholly owned subsidiary BioSymetrics has unveiled a proprietary AI-based zebrafish screening platform designed to rapidly identify medical countermeasures for neurotoxic chemical agents, including weaponized substances like Sarin. The platform has been integra...
Read More
Enochian Biosciences
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Informationen zu Product Placements

 

BARRISTA SMART * AD

P R O D U C T   S U G G E S T I O N S